Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Inventory (2022 - 2025)

Historic Inventory for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $365000.0.

  • Orchestra BioMed Holdings' Inventory rose 5598.29% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $365000.0, marking a year-over-year increase of 5598.29%. This contributed to the annual value of $173000.0 for FY2024, which is 1849.32% up from last year.
  • Orchestra BioMed Holdings' Inventory amounted to $365000.0 in Q3 2025, which was up 5598.29% from $185000.0 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Inventory high stood at $365000.0 for Q3 2025, and its period low was $70000.0 during Q2 2024.
  • For the 4-year period, Orchestra BioMed Holdings' Inventory averaged around $187166.7, with its median value being $175500.0 (2023).
  • In the last 5 years, Orchestra BioMed Holdings' Inventory plummeted by 6067.42% in 2024 and then skyrocketed by 16428.57% in 2025.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Inventory stood at $276000.0 in 2022, then plummeted by 47.1% to $146000.0 in 2023, then grew by 18.49% to $173000.0 in 2024, then skyrocketed by 110.98% to $365000.0 in 2025.
  • Its Inventory stands at $365000.0 for Q3 2025, versus $185000.0 for Q2 2025 and $135000.0 for Q1 2025.